# Tetratherix Investor Presentation March 2026

Tetratherix™

# Why does the world need Tetratherix?

## The evolving dynamics of the global healthcare system are demanding innovative and cost-effective biomaterials

**Trends in healthcare delivery**

### Rising patient expectations

Patients are increasingly demanding higher quality of care with a particular focus on **reducing recovery times** and **lower risk of complications** (e.g. infection, blood loss, pain) - which is also a driver of increasing healthcare costs for patients and payers

### Need for cost-effective, decentralised care

Increasing global healthcare spending and demand for healthcare services is necessitating investment in **cost-effective tools and treatments**, including those that can be **delivered outside a traditional hospital setting**, to minimise burden on the healthcare system

**70m** Estimated 70 million US outpatient procedures per year and increasing by >6%

**60%** Nearly 60% of outpatients are operated on in ASCs

**2X** These numbers are forecast to double over the next 10 years

Orthopaedic, ophthalmology, urology and neuro/pain are the main segments being disrupted

Tetratherix™

# How does Tetramatrix help facilitate this shift?

## Our Tetramatrix platform is best positioned to address the clinical demands that are central to the evolution

**Minimally invasive delivery**
Water-based solution injected through fine gauge needle

**Seamlessly integrated into existing workflows**
No additional equipment required

**Tetramatrix™**

**Safe, biocompatible and bioresorbable**
No foreign body reaction upon application

**Low cost, scalable production**
Non-labour intensive, low cost and readily available materials

Tetratherix™

# Tetramatrix™ platform technology is the world's first biostealth fluid matrix

## Intelligent

A **decade of polymer programming** has led to an ideal consistency & physical performance. The material is an **injectable fluid** to avoid causing damage to the body during its application. Using physiological temperature, material transitions into a 3D matrix.



## Modular

A biomaterial platform built with unique polymer programming **akin to "medical Lego®"** to form implantable products to solve a wide range of clinical problems. The platform has built products for 7 anatomical sites with 3 chemical entities derived from the core technology.




## Biomimetic

The matrix has **similar water content and mechanical properties** to natural tissue, and therefore is **impervious to the body**, helping heal injuries or physically manipulating the body during surgical interventions.

**Human Histological Evaluation**

- Inflammatory Fibrovascular (IFV)
- Tissue ingrowth




## Safe

Due to the **unique polymer programming of the material**, once the matrix serves its purpose, the material **gradually and safely bioresorbs** in the body with no impact locally or systemically. Biocompatibility data from multiple clinical trials show no impact to internal organs or blood markers.

**Preclinical studies (equivalent to 5 litre product administration)**

- ✓ No effects on blood markers for internal functions of liver, kidney and spleen
- ✓ Fully resorbed and excreted from the body

Tetratherix™

# Derived medical devices from the Tetramatrix™ platform technology span multiple large franchises and significant near-term commercial opportunities

## Bone Regeneration

Flowable bone graft extender for orthopaedic applications



Bone graft extender for dental surgeries



## Tissue Healing

Intraoperative solution to reduce scar formation after surgeries







## Tissue Spacing

Spacer during cataract surgeries



Prostate Spacer for radiation therapy



## An initial addressable combined market of $USD6.8B


*TAM Defined by 3 initial franchises only

Tetratherix™

# Different clinical needs. Different market segments. Single Tetramatrix™ platform technology.

## Think of us like a software platform business...

The Tetramatrix biomaterial is our **core 'platform' technology**. We have completed the foundational safety, efficacy and manufacturing work which is transferable across different clinical applications of the platform.

We will **license the IP** in a specific field to a leader in the segment. These partners complete the "final 20%" to turn the application into a clinical product. We will then manufacture the product and supply at attractive unit economics to our industry leading partners who distribute it though their sales channels.

We will enjoy periodic milestone payments as well as a steady flow of income from product supply - a dual revenue source brings the best of both worlds.



Commercial model

Tetratherix™

# A capital light model with compounding revenue

While we build our own production and R&D infrastructure, we avoid committing capital on establishing multiple sales & distribution networks by utilising the capabilities of our partners' established teams.

Importantly, we operate in unison with our partners. Our high margin revenue compounds over time by adding new partnerships and launching new products.

Similar to a 'build-to-buy' model, we partner differently to, and at earlier stages than, traditional medtech companies. Therefore, our return profile is different and not built on expectations of an eventual acquisition.

**This unique and attractive model is enabled by:**

- A platform technology that allows parallel developments
- Advanced manufacturing with economies of scale
- Partnerships with leading players who are motivated to sell over a long time
- A patient & deliberate strategy



Tetratherix™

# An operational moat with IP Leadership built on a global R&D infrastructure. This sets us apart.


bsi.

**Supported by complete IP coverage**

Patent stack with 36 granted patents from 9 families of patent, extending to 2044 & beyond and fully owned by Tetratherix

**R&D investment at 39% of total expenditure Total $3.1m +160% vs H1Fy25**




*R&D includes specific projects, directly attributable staff, laboratory costs, trademarks and patents

**+160% vs H1 FY25**



Tetratherix™

# Derived medical devices from the Tetramatrix™ platform technology span multiple large franchises and significant near-term commercial opportunities

## Expansion by Design: Transitioning from Three Pillars to a Four-Node Ecosystem

### Bone Regeneration

Flowable bone graft extender for orthopaedic applications



Bone graft extender for dental surgeries



### Tissue Healing

Intraoperative solution to reduce scar formation after surgeries







### Tissue Spacing

Spacer during cataract surgeries



Prostate Spacer for radiation therapy



**An initial addressable combined market of $USD6.8B***

*TAM Defined by 3 initial franchises only


**Same core technology, same material and interchangeable dataset**

Tetratherix™



# Introducing STEPP – Tetratherix's enabling vehicle for novel delivery of compounds

**The STEPP project has been in stealth mode and under deep development for more than 5 years, including global R&D studies with several big pharma partners.**

# STEPP | Mode of Action for STEPP Drug Delivery

## The Tetramatrix™ platform's STEPP - the enabling vehicle for novel delivery of compounds

The polymer system is negatively charged and the presence of hydrophilic + hydrophobic groups within PNPHO create a protective micelle-like layer around biologics.




A unique protective layer around the cargo that means the cargo doesn't stick together or get ruined during delivery.

Because the cargo doesn't stick together and 'clump', the particle size is smaller for better transportation

# STEPP | An Introduction

## Tetramatrix™ platform – vehicle enabling effective nasal delivery of compounds

### 1 Biological

- Our delivery system facilitates **sustained release** of cargo
- STEPP has been shown to **reduce enzymatic** degradation of incorporated cargo in multiple applications
- Allows **unique routes** for systemic delivery

### 2 Physical

- STEPP forms a **protective micelles** around incorporated cargo to allow for stability and protection
- STEPP is a **stabilising agent** for the cargo
- STEPP **retains the cargo** at the delivery site

### 3 Commercial

- STEPP is **simple to incorporate** with routine manufacturing
- STEPP is **proprietary** - allowing a unique product offering
- STEPP may allow for 'surprising synergies' and by extension - facilitates **new formulation patents** for off-patent candidates




# STEPP | Physical Adhesion Is a Big Deal

## The use of the carrier in different formulations allows direct spray with no nose or throat run off

The following example is with mRNA/LNP (global big pharma collaboration), representing a challenging test for nasal delivery and mucosa adhesion.







The nose and throat runoff affect the reproducibility of the dosage without the carrier system.

**60% product loss**

# STEPP | Physical Adhesion Is a Big Deal

## The use of the carrier in different formulations allows direct spray with no nose or throat run off.

The following example is with mRNA/LNP (Global big pharma collaboration), representing a challenging test for nasal delivery and mucosa adhesion.




The nose and throat runoff affect the reproducibility of the dosage without the carrier system.

**60% product loss**




Wide coverage and no nose- and throat- runoff with the carrier system.

# STEPP | Mode of Action for STEPP Drug Delivery

## STEPP delivers cargo and maintains activity of different cargos before & after administration

Different in vitro and in vivo preclinical studies have confirmed the potential of the technology to deliver different compounds. STEPP controls the release of cargo and allows both systemic and direct-to-brain delivery of different actives.

**1 Insulin/GLP-1**

- Confirmation of stability
- Confirmation of sustained release
- Animal study to show delivery

**2 mRNA/LNP**

- Confirmation of stability
- Confirmation of sustained release
- Confirmation of biological activity post release

**3 Analgesics & Antibiotics**

- Confirmation of stability
- Confirmation of sustained release
- Confirmation of in vitro activity post release




Controlled release of active cargos (GLP-1 etc) in the presence of the carrier. Free cargo displayed a burst release, whereas with 25 mg/ml (TP025+) and 35 mg/ml (TP035+) of PNPHO, the burst release is prevented.

The presence of the carrier system prevent the degradation of the cargo in mucosa via enzymes. These results suggest that the carrier can increase the bioavailability of GLP-1 or other actives via nasal delivery.



# Continuous intelligence: real-world evidence acquisition at the biological frontier

Tetratherix™ + superpower

## The Partner

**Pioneers of 'Pharma 2.0':** Superpower is a sophisticated US-based precision health company that moves beyond traditional reactive medicine by utilising an AI-driven 'Test, Prescribe, Optimise' model.

**Data-Driven Patient Care:** Their platform integrates comprehensive biomarker tracking - including blood panels and metabolic screening - to proactively identify health issues and generate personalised protocols that combine pharmaceuticals with lifestyle interventions.

**Strategic Market Access:** The partnership utilises an agile 'compounding-first' model, allowing Tetratherix to start collecting real world evidence in the US GLP-1 and peptide markets immediately under existing regulatory frameworks.

**Strong Financial & Consumer Backing:** Superpower is a highly capitalised partner backed by US VC and high profile individuals. The health platform currently has a significant waitlist of over 200,000 people.

## The Agreement

**Exclusive R&D Agreement:** Tetratherix will receive an exclusive licensing fee for the use of its technology in the R&D fields of nasal drug delivery and the subcutaneous delivery of select compounds. This fee is structured as a annual payment of US$3m payable on renewal by Supwerpower for up to 10 years.

**Ongoing Polymer Sales:** Beyond licensing, the company will also generate revenue through the sale of the Tetramatrix™ polymer. As Superpower scales its customised product offerings, Tetratherix will act as the primary supplier of this essential biostealth carrier.

**Expedited Pathway to Revenue:** This allows Tetratherix to divert from the traditional, multi-year pharmaceutical development cycles and generate real world demand and an immediate channel to commercialise assets like nasal GLP-1s - generating revenue in FY26.

**Real-World Evidence Generation:** The partnership serves as a high-scale, revenue-generating pilot that provides direct access to real-world use evidence by gathering patient insights on efficacy and tolerance.

## The Opportunity

**Unprecedented Market Scale:** The global market for GLP-1 agonists is currently the fastest-growing sector in pharmaceutical history, projected to exceed $100b by 2030. This opportunity extends into the broader peptide and hormone replacement therapy markets, where the shift toward quality of life treatments is driving a wave of  demand.

**High-Value Comparable Benchmarks:** The industry is currently in a 'delivery leadership' arms race, evidenced by multi-billion dollar acquisitions of carrier technologies. Notable benchmarks include Novo Nordisk's $1.8b acquisition of Emisphere for its SNAC oral delivery technology and Pfizer's recent investment in Metsera for its HALO delivery system.

**The Delivery Holy Grail:** While the efficacy of our targets are well-established, the industry's primary hurdle has shifted from the 'active ingredient' to the 'delivery system'. Nasal delivery is considered the holy grail because it offers the high efficacy of an injection with the frictionless convenience of a spray, potentially capturing the >15% of patients who currently opt out of treatment due to needle fatigue or phobia.

# EXECUTION OF THE STRATEGY SINCE IPO

Near Term Milestones

# 9 months after ASX listing – Efficient use of Funds and Strong Cash Position




#anchoredbyscience

Near Term Milestones

# 9 months after ASX listing – Efficient use of Funds and Strong Cash Position

| | FY2026 | | | | FY2027 | |
|---|---|---|---|---|---|---|
| DENTAL | ✓ Henry Schein Supply &Licensing Agreement Execution | ✓ Data read-out from the FDA study | FDA Submission | FDA Clearance | | |
| ORTHOPAEDIC | | Master Partnership Agreement Execution | Supply and Licensing Agreement Execution | FDA Submission | FDA Clearance | |
| ONCOLOGY | ✓ FDA Pre-submission/ Regulatory Pathway Defined | ✓ Tutelix First In Human Cohort 1 Read-out | ✓ Quality & Supply Agreement Execution | ✓ US/AU Capital Raise | Tutelix Primary End Point for Cohort 2 | Pivotal Clinical Trial Initiation |
| OPHTHALMIC | ✓ BioOptix Licensing Agreement | ✓ Strategic Global Partnership | ✓ US / AU Capital Raise | Preclinical Data Read-out | | FDA Pre-submission & Regulatory Pathway |
| SURGICAL SITE MGMT | ✓ Cohort 2 Commenced | ✓ Year 1 Follow up for Cohort 1 results published | ✓ TetraDerm Cohort 3 Initiation (Major Surgeries) | FDA Pre-submission & Regulatory Pathway | Primary End-point Cohort 2 | |
| OPERATIONS | ✓ IGP Grant | ✓ ISO13485 surveillance Audit | ✓ New Facility Signed and production begins | ✓ Board Restructure | | MDSAP Stage 1 Audit |




Revenue and other income +291% vs H1 Fy25, driven by IGP grant and R&D tax incentive to fuel growth

Strong cash on hand position of $21.6million
Operating cash flow at $~2.2m per quarter




Overhead spend per employee *at $0.27million reflecting capital light model




* Overhead spend per employee excls Direct R&D project opex

Relentless Execution

# Commercial Milestones & Partnerships




Global Distribution and Supply Agreement with the world's largest provider of healthcare solutions for dental market launch.

HENRY SCHEIN®

R&D agreement with the world's biggest ophthalmology technology company to develop next generation ophthalmic devices.

Alcon

Tutelix successfully completed its Series A capital raise to expedite clinical trial and launch in the US - supported by US clinicians.

Tutelix™

TTX has now excitingly announced a new US partnership in precision medicine with Superpower Health.

superpower

Relentless Execution

Tetratherix™

# Technical & Clinical Milestones

| | FY2026 | | | | FY2027 |
|---|---|---|---|---|---|
| DENTAL | ✓ Henry Schein Supply &Licensing Agreement Execution | ✓ Data read-out from the FDA study | FDA Submission | | FDA Clearance |
| ORTHOPAEDIC | | Master Partnership Agreement Execution | Supply and Licensing Agreement Execution | FDA Submission | FDA Clearance |
| ONCOLOGY | ✓ FDA Pre-submission/ Regulatory Pathway Defined | ✓ Tutelix First In Human Cohort 1 Read-out | ✓ Quality & Supply Agreement Execution | ✓ US/AU Capital Raise | Tutelix Primary End Point for Cohort 2 | Pivotal Clinical Trial Initiation |
| OPHTHALMIC | ✓ BioOptix Licensing Agreement | ✓ Strategic Global Partnership | ✓ US / AU Capital Raise | Preclinical Data Read-out | FDA Pre-submission & Regulatory Pathway |
| SURGICAL SITE MGMT | ✓ Cohort 2 Commenced | ✓ Year 1 Follow up for Cohort 1 results published | ✓ TetraDerm Cohort 3 Initiation (Major Surgeries) | FDA Pre-submission & Regulatory Pathway | Primary End-point Cohort 2 |
| OPERATIONS | ✓ IGP Grant | ✓ ISO13485 surveillance Audit | ✓ New Facility Signed and production begins | ✓ Board Restructure | MDSAP Stage 1 Audit |

Initiation and successful progression of prostate spacer trial, 15 patients treated with solid indications of performance.




Progression of TetraDerm clinical trial and achieving 1 year follow up data from the cohort 1 of the trial with indications of efficacy.




FDA studies progressing as planned, 100% pass rate for all in vivo implantations safety and performance studies.

FDA

#anchoredbyscience

Near Term Milestones

# Relentless Operational Execution




- Australian Federal Government industry grant, $3.3m to co-fund the planned development activities.

Australian Government
Department of Industry, Science and Resources
Industry Growth Program
AusIndustry

- Peter Grey (Co-Founder of Zip) joined the board of directors further strengthening the board to navigate highly regulated global market.
- Completed and successfully passed ISO13485 surveillance audit with construction initiated in the new site for 10X expansion.
- On-budget delivery of milestones and cash on hand $21.6m (from $25m raised in IPO and $9m from pre-IPO).
- Ongoing and meaningful disclosures to the market:

| 15 | 8 | 3 | 4 |
|---|---|---|---|
| Total Reports and Market Updates | Technical and Commercial Updates | Clinical trial updates and news | Partnership and commercial validation |

Tetratherix™

# Not simply a science experiment. Tetramatrix™ provides real world economics.

| | Bone Regeneration | Tissue Spacing | Tissue Healing |
|---|---|---|---|
| TAM | US$3.4bn | US$1.3bn | US$2.1bn |
| Payer | Patient out-of-pocket | Reimbursed (US) | Patient out-of-pocket |
| Expected GM[1] for Partner | 70-80% | ~80-90% | ~70-80% |
| Expected GM for TTX | 60-70% | ~75-85% | ~60-70% |

We verify the final end user pricing and the gross margin targets for our strategic partners before progressing

1. Weighted Blended Standard Gross Margin

Manufacturing

# Advanced manufacturing and operations

## We have established advanced manufacturing in Sydney. To meet growing demand, a new lease agreement has been executed and the new facility is planned to be commissioned in 2026, with a modular design to allow us to quickly scale as needed.

### Our manufacturing process is:

#### Highly Scalable with supply chain security

- Our manufacturing process is **designed in a 'POD' framework whereby every POD can operate independently**
- The POD has a foot print of **200 sqm**, and can be replicated multiple times without our facility floorspace
- Allows multiple X increases in the production capacity in a **fast and controlled manner**

#### De-risked

- We have previously **increased our production yield per batch from laboratory scale (10 g per batch) to a commercial scale (1.2kg)** through multiple cycles of process optimisation and scale up
- The production process is not labour-intensive and requires only off-the-shelf equipment
- All raw materials are **catalogue products and easily accessible** from multiple suppliers, de-risking any supply chain risk
- A new, larger site in Alexandria, Sydney has been identified **with the lease now executed and signed**

Manufacturing POD

Manufacturing

# The New TTX HQ and Manufacturing campus construction on track

We have executed a lease agreement (10 + 5 Years) and have secured relevant approval to start construction at the site. The project in on track to move the headquarter to the new site in FY26 and the first formal production in FY27.



**Manufacturing upscale**
**$2.2m in H1Fy26, 22% of $11m UOF**






Near Term Milestones

# TTX continues to evolve and plans to relentlessly execute into FY27 and beyond



# APPENDIX

# Bone Regeneration – Dental & Orthopaedic

Tetratherix™

## A universal enabling solution to simplify complex oral & dental procedures

### Tegenix | Dental Bone Graft

**Partners**

HENRY SCHEIN®

**Key Dates From the Prospectus**

Supply Agreement in FY26
FDA Clearance in FY26
Market Launch in FY26 in the US




Amenable to different graft particles and easy to mix




Mouldable and shapable putty




Easy to handle and easy to manipulate



Gentle press-fit into the site and adherence without primary closure

### TegenEOS | Orthopaedic Bone Graft

**Partners**

**Currently Under Due Diligence with multiple key players**

**Key Dates From the Prospectus**

Supply Agreement in FY26
FDA Clearance in FY26
Market Launch in FY27 in the US



Flowable mixture of Tegenix and bone graft material

Fills the void and keep grafts geometrically in place

Tegenix resorption allowing cell and blood vessel ingrowth for effective activation of grafts

Expedited healing

# Tegenix | Dental Bone Graft

Tetratherix™

## On-track commercial launch in 2026 as outlined in the prospectus



# TegenEOS | Orthopaedic Bone Graft

Tetratherix™

## On-track for commercial launch in 2026 as outlined in the prospectus

## Strategic pivot in partnership assessment and still on-track for commercial launch in FY27 as outlined in the prospectus

**Strategic Realignment - Prioritising Highest-Return Partnerships**



One of our leading potential ortho partners recently made a strategic shift in product and corporate strategy. This shift meant our long term ortho stability may have been challenging (specifically in the US shift to day-surgery clinics) which would have increased integration complexity and execution risk over the long term. As such, we have deliberately chosen to refocus our due diligence efforts on 2 other leading ortho partners - the advantage of our partnership model.

Two partners now in late stage due diligence

- Partner A: Global market leader with extremely strong enterprise channels and strong revenue growth (in a flat market), offset by legacy integration complexity.
- Partner B: High-growth global scaler with flexible commercial terms and co-innovation upside, offset by execution risk if priorities shift.

Either partner materially strengthens the TTX portfolio and we continue to progress the discussions for final decisions on track for 2026.

Tutelix™ | Tissue Spacing – Oncology

Tetratherix™

# Safe & easy to use solution for more effective & simpler spacing in radiation oncology

Tutelix™ is intended for use as a spacer to reduce side effects to surrounding tissue during radiation therapy to treat prostate cancer. It is easily injected and is gradually resorbed by the body and excreted over time (12 weeks) without harm to any internal organs



Injection to the space between prostate/ rectum

Space generation to reduce side effects to rectum during radiation

## Key features

### Procedure Optionality

**1** A water-based solution makes the product amenable to single injection after hydrodissection OR as multiple gradual injections, two commonly used techniques.

### Simple to adjust (+/- volume)

**2** Activated organically by body temperature, the solution transitions into a hydrogel. The hydrogel is smooth, flowable and can be immediately reversed with cold-saline. The hydrogel breaks down to non-toxic components and bioresorbs within 3 to 6 months completely.

### Visible to physicians under both CT-scan and ultrasound

**3** In contrast to incumbent products, the product is visible under ultrasound during administration and under Computed Tomography without enhancement which allows for a safer, simpler, more accurate and cost-effective outcome when delivering radiotherapy.

# Tutelix™ | Tissue Spacing - Oncology

Tetratherix™

## Tutelix progressed first in human clinical trial with promising results completed a priced round of funding from AU and US investors

A Product Insertion and Visibility of prostate




B Tutelix spacer generated space to reduce radiation to rectum







During the administration process and product gelation, high visibility of prostate via trans rectal ultrasound (TRUS) was maintained.

Spacers retained their structure in all patients and, to date, excellent product stability has been achieved post-implantation throughout the radiotherapy delivery.

**ZERO**

Reported Adverse Events from any of the patients treated to date. Multiple patients reach 6 months follow up time point.

After injection (t=0) | Three months | Six months



# TetraDerm | Tissue Healing

## The world's first intraoperative scar prevention solution

TetraDerm is the only flowable matrix that can be used intraoperatively to provide an internal cushioning effect to physically decrease mechanical tension and dead space, therefore reducing scar formation after any surgery, such as surgical reconstruction, arthroplasty and caesarean procedures




## Key features

### 1 Easy to apply and able to be used intraoperatively

A flowable dermal matrix that forms a uniform hydrogel within dermal layers without the need for any external stimuli, such as light or chemical reaction- gelation is triggered by physiological temperature.

### 2 Superior efficacy in tissue remodelling and would closure

The mimetic of the hydrogel allows biological integration of the hydrogel within the host tissue and provides a physical scaffold for cellular regeneration and skin remodelling.

### 3 Decreases myofibroblast activity and scar formation

Mechanical tension is the driving force known to increase myofibroblast activity and consequently scar formation. The matrix provides an internal cushioning effect to reduce mechanical tension and dead space, thus preventing scar formation.

# TetraDerm | Early Clinical Findings

## Vancouver Scar Scale (VSS) score of < 2 at all time points

All measurements for all patients were very low (minimal scaring) at all time points. The important time points are 6 weeks for acute response and long term stable responses at 12 months displayed minimal scaring at the site.




## Safety measures that confirms the overall mode of action for TetraDerm

| Follow-up | VSS Parameters | | | | Total Average |
|---|---|---|---|---|---|
| | Vascularity (0-3) | Pigmentation (0-2) | Pliability (0-5) | Height (0-3) | |
| Week 6 | 0.1 ± 0.35 | 0 | 0.4 ± 0.5 | 0.4 ± 0.7 | 0.9 ± 1.1 |
| Month 3 | 0.1 ± 0.38 | 0 | 0.4 ± 1.3 | 0.4 ± 0.8 | 1.8 ± 1.7 |
| Month 6 | 0.8 ± 0.46 | 0 | 0.3 ± 1.0 | 0.3 ± 0.7 | 1.6 ± 2.0 |
| Month 12 | 0.4 ± 0.52 | 0 | 0.3 ± 1.1 | 0.3 ± 0.7 | 1.1 ± 2.1 |

**70** Oldest patient treated in the trial with VSS of <1 at all time points
**years of age**

**9** relatively large wounds with no healing issues
**cm wound length**

**0** No reports of seroma formation in any of the treated wounds
**seroma formation**

**0** No reports of inflammation from 2 weeks onwards in any of the patients
**inflammation**